In 2008, the US Surgeon General declared venous thromboembolism (VTE) a major public health concern, leading to a call to action for VTE prevention.
1,2 Furthermore, many national agencies, including the Centers for Medicare and Medicaid Services, have placed VTE in the category of “reasonably preventable” hospital-acquired conditions.
3 In 2012, Thorson et al
4 showed that, in high-risk trauma patients with a Risk Assessment Profile (RAP) score of 10 or higher, routine screening venous duplex ultrasonography identified a VTE rate of 28%, even with standard thromboprophylaxis (TPX). Most trauma centers have adopted a standard fixed-dose low-molecular-weight (LMW) heparin sodium as TPX, rather than unfractionated (UF) heparin. Despite this TPX regimen, the VTE rate continues to be high in the trauma population.